SARS-CoV-2 Main Protease Inhibitors via Structural Parameter Changes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19 lack effective options to inhibit the main protease (MPro) of SARS-CoV-2, which is crucial for viral replication and pathogenesis, necessitating the development of potent small molecule medicines.
Innovation Solution
The disclosure provides a series of compounds with specific chemical formulas that can inhibit the SARS-CoV-2 main protease (SC2MPro), potentially offering a treatment option for COVID-19 by targeting the enzyme essential for viral biology.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for COVID-19, then existing therapeutic options are maintained, but effective inhibition of SARS-CoV-2 main protease is not achieved
Solution Approach 1:
The patent applies parameter changes by systematically varying chemical structures of small molecule compounds (changing molecular parameters) to achieve potent inhibition of SARS-CoV-2 main protease. Multiple compounds with different chemical formulas (I, II, III, IV, V, VI, VII, VIII, IX, X) are designed with modified R groups and structural parameters to optimize protease inhibition effectiveness.
2Reliability
If small molecule medicines are developed to inhibit MPro, then viral replication can be disrupted, but the complexity of drug development increases
Solution Approach 1:
The patent applies segmentation by dividing the complex drug development process into systematic structural modifications. Each compound series (I-X) represents a segmented approach where specific R groups and molecular components are varied independently to achieve the desired protease inhibition while managing structural complexity through organized chemical space exploration.
Data Source
AI summary
The present disclosure relates to certain molecules, pharmaceutical compositions containing them, and methods of using them to treat viral infections.